氨酸的限制抑制了胰腺癌的扩散,同时抑制了JAK2/STAT3通路
Manabu Maebashi1, Kentaro Miyake1, Jun Yamamoto1
1Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
概括
氨酸限制 (MR) 通过抑制JAK2/STAT3通路和降低NF-kB来抑制胰腺癌 (PC) 的生长. 这项研究揭示了MR在PC中的抗瘤机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 营养科学 营养科学
背景情况:
- 氨酸限制 (MR) 在各种癌症中显示出抗瘤作用,包括胰腺癌 (PC).
- 在PC中MR的抗癌活性背后的精确分子机制尚未完全理解.
- 用蛋白质组分析来阐明MR对PC的影响.
研究的目的:
- 调查胰腺癌 (PC) 中氨酸限制 (MR) 的潜在分子机制.
- 在PC细胞系和体内模型中识别受MR影响的关键蛋白质和通路.
主要方法:
- 人类PC细胞系在标准和MR条件下进行培养.
- 用蛋白质组分析和发明路径分析 (IPA) 来识别差异表达的蛋白质.
- 验证是在体内小鼠模型中使用西部涂抹,实时PCR,ELISA和免疫组织化学进行的.
主要成果:
- 在实验室中,MR显著抑制了胰腺癌细胞的增殖.
- 蛋白质组和验证研究显示,在MR治疗的细胞中,STAT3和NF-kB的表达减少.
- 在体内研究表明,MR组的瘤体积显著减少,并抑制了STAT3表达.
结论:
- 氨酸的限制有效地抑制了胰腺癌的生长.
- 在胰腺癌中,JAK2/STAT3信号通路和NF-kB是MR的关键标.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


